Regulatory Environment Analysis Sample Clauses

Regulatory Environment Analysis. In coordination with the City’s current zoning update initiative, the Consultant Team will review and analyze existing land use codes for the corridor to determine areas for improvement and make recommendations for policy and code changes. Zoning overlays should also be addressed in this analysis, with an emphasis on Form-Based Code. Deliverables: • Summary of Market Demand and Redevelopment Incentives Analysis • Summary of Redevelopment Opportunities and Challenges Analysis • Summary of Regulatory Environment Analysis • Recommendations from Land-Use Analysis • Zoning and Development Code Review and Analysis • Proposed Zoning Overlays including Recommendations for Modifications and/or Proposed Development Incentives/Strategies • Form-Based Code Recommendations TASK 6 – DRAFT DIVISION STREET CORRIDOR MASTER PLAN The Consultant Team will prepare a Draft Division Street Corridor Master Plan document compiling the work outlined in the previous tasks. The following will be included: • Case studies of successful programs and implementation strategies pertinent to the City of Arlington • Existing Conditions Analysis • Transportation Infrastructure Improvement Analysis • Land Use Revitalization Strategies • Implementation Plan and Table of Action Steps • Appendices including public input summaries, cost estimates, maps, etc. The Consultant Team will submit the draft plan to the DCAC, PRC, and the public for review. The final draft plan will be made available in paper and digital form. The digital form will be made available on the project website for easy download. Deliverables: • Draft plan (digital and hardcopy) TASK 7 – FINAL DIVISION STREET CORRIDOR MASTER PLAN The Plan should integrate comments from focus group and public meetings. The Plan should include, but is not limited to the following: an acknowledgment page, a table of contents, list of figures and tables, an executive summary, the findings of all the tasks in Phase One through Five, conclusion, appendices, and a glossary. The PRC will review the document and provide comments before the consultant finalizes the plan. The report will be high-quality with clear images and illustrations with written text that is free of typographical and grammatical errors. All maps and tables will be properly cited and contain keys when appropriate. The consultant will apply its internal quality assurance controls to achieve a high quality report. Neither NCTCOG nor the City of Arlington will undertake quality control f...
Sample 1
AutoNDA by SimpleDocs

Related to Regulatory Environment Analysis

  • Data Analysis In the meeting, the analysis that has led the College President to conclude that a reduction- in-force in the FSA at that College may be necessary will be shared. The analysis will include but is not limited to the following: ● Relationship of the FSA to the mission, vision, values, and strategic plan of the College and district ● External requirement for the services provided by the FSA such as accreditation or intergovernmental agreements ● Annual instructional load (as applicable) ● Percentage of annual instructional load taught by Residential Faculty (as applicable) ● Fall Full-Time Student Equivalent (FFTE) inclusive of dual enrollment ● Number of Residential Faculty teaching/working in the FSA ● Number of Residential Faculty whose primary FSA is the FSA being analyzed ● Revenue trends over five years for the FSA including but not limited to tuition and fees ● Expenditure trends over five years for the FSA including but not limited to personnel and capital ● Account balances for any fees accounts within the FSA ● Cost/benefit analysis of reducing all non-Residential Faculty plus one Residential Faculty within the FSA ● An explanation of the problem that reducing the number of faculty in the FSA would solve ● The list of potential Residential Faculty that are at risk of layoff as determined by the Vice Chancellor of Human Resources ● Other relevant information, as requested

  • Statistical Analysis 31 F-tests and t-tests will be used to analyze OV and Quality Acceptance data. The F-test is a 32 comparison of variances to determine if the OV and Quality Acceptance population variances 33 are equal. The t-test is a comparison of means to determine if the OV and Quality Acceptance 34 population means are equal. In addition to these two types of analyses, independent verification 35 and observation verification will also be used to validate the Quality Acceptance test results.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Statistical Sampling Documentation a. A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO.

  • Disturbance Analysis Data Exchange The Parties will cooperate with one another and the NYISO in the analysis of disturbances to either the Large Generating Facility or the New York State Transmission System by gathering and providing access to any information relating to any disturbance, including information from disturbance recording equipment, protective relay targets, breaker operations and sequence of events records, and any disturbance information required by Good Utility Practice.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Financial Viability and Regulatory Compliance 4.6.1 The Contractor warrants and represents that its corporate entity is in good standing with all applicable federal, state, and local licensing authorities and that it possesses all requisite licenses to perform the services required by this contract. The Contractor further warrants and represents that it owes no outstanding delinquent federal, state, or local taxes or business assessments.

  • Material Safety Data Sheet Seller shall provide to Buyer with each delivery any Material Safety Data Sheet applicable to the work in conformance with and containing such information as required by the Occupational Safety and Health Act of 1970 and regulations promulgated thereunder or its State approved counterpart.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

Time is Money Join Law Insider Premium to draft better contracts faster.